Treatment of ocular inflammatory disorders with daclizumab

This publication has 10 references indexed in Scilit:

• Treatment of steroid refractory acute and chronic graft‐versus‐host disease with daclizumab
  British Journal of Haematology, 2001
• Treatment of recalcitrant psoriasis with daclizumab
  British Journal of Dermatology, 2001
• Daclizumab (Zenapax®) inhibits early interleukin-2 receptor signal transduction events
  Transplant Immunology, 2000
• Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel
  American Journal of Ophthalmology, 2000
• THE SAFETY AND EFFICACY OF A TWO-DOSE DACLIZUMAB (ZENAPAX) INDUCTION THERAPY IN LIVER TRANSPLANT RECIPIENTS1
  Transplantation, 2000
• Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody
  New England Journal of Medicine, 2000
• Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial
  Proceedings of the National Academy of Sciences, 1999
• Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
  New England Journal of Medicine, 1998
• Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases.
  The Journal of Immunology, 1997
• Immunosuppressive Therapy for Progressive Ocular Cicatncial Pemphigoid
  Published by Elsevier ,1982